Liraglutide (Victoza) has been a diabetes therapeutic option for the past 5 years. It has recently received the FDA approval as Saxenda, at higher doses, as an adjunct treatment for weight loss in adults in combination with a reduced calorie diet and increased physical activity. Saxenda has been associated with medullary thyroid carcinoma (in animal models) and acute/necrotizing pancreatitis. As a result, the FDA is requiring a Risk Evaluation and Mitigation Strategy (REMS) for this medication to help inform patients and clinicians about the risks liraglutide carries. Given the REMS status, how do you feel about liraglutide therapy for weight loss? What are your typical recommendations for patients interested in weight loss?
For more information, please click here.
Image courtesy of [Hyena Reality]/http://www.freedigitalphotos.net